Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
The latest update is out from Malin ( (MLLNF) ).
Roche Holdings has completed a tender offer to acquire all outstanding shares of Poseida Therapeutics, a company in which Malin holds a 12% stake. The acquisition will deliver initial net proceeds of approximately $106.5 million to Malin, with potential additional earnings of up to $47.3 million through contingent value rights. Following the merger, Poseida will become a wholly owned subsidiary of Roche and will no longer be traded on the Nasdaq Global Select Market. Malin’s board is evaluating options to return the surplus capital to its shareholders.
More about Malin
Malin Corporation plc is a company focused on investing in highly innovative life sciences companies.
YTD Price Performance: 0.0%
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $182.9M
See more data about MLLNF stock on TipRanks’ Stock Analysis page.
